136 related articles for article (PubMed ID: 9759997)
1. 7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells.
Rohde D; Raffenberg G; Kaviani S; Wolff J; Jakse G
Urol Res; 1998; 26(4):243-7. PubMed ID: 9759997
[TBL] [Abstract][Full Text] [Related]
2. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
Lee JH; Naito M; Tsuruo T
Cancer Res; 1994 May; 54(9):2398-403. PubMed ID: 8162587
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
4. Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149.
Ishida T; Nishio K; Kurokawa H; Arioka H; Fukumoto H; Fukuoka K; Nomoto T; Yokote H; Hasegawa S; Saijo N
Int J Cancer; 1997 Sep; 72(5):865-70. PubMed ID: 9311606
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
Dirix LY; Gheuens EE; van der Heyden S; van Oosterom AT; De Bruijn EA
Anticancer Drugs; 1994 Jun; 5(3):343-54. PubMed ID: 7919460
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
7. Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T; Kasahara K; Shibata K; Numata Y; Heki U; Shirasaki H; Iwasa K; Fujimura M; Matsuda T
J Cancer Res Clin Oncol; 1996; 122(1):21-6. PubMed ID: 8543588
[TBL] [Abstract][Full Text] [Related]
8. Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Yen WC; Schmittgen T; Au JL
Pharm Res; 1996 Dec; 13(12):1887-91. PubMed ID: 8987090
[TBL] [Abstract][Full Text] [Related]
9. Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
Verma A; Degrado J; Hittelman AB; Wheeler MA; Kaimakliotis HZ; Weiss RM
BJU Int; 2011 Apr; 107(7):1154-61. PubMed ID: 20735383
[TBL] [Abstract][Full Text] [Related]
10. [Blood and tissue levels of mitomycin C after intravesical instillation].
Flüchter SH; Hlobil H; Harzmann R; Rothe KF; Bichler KH
Urol Int; 1983; 38(6):321-8. PubMed ID: 6419427
[TBL] [Abstract][Full Text] [Related]
11. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation.
McAdam SR; Knox RJ; Hartley JA; Masters JR
Biochem Pharmacol; 1998 Jun; 55(11):1777-83. PubMed ID: 9714295
[TBL] [Abstract][Full Text] [Related]
12. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
Egelmeers A; Dirix LY; Lyczek J; De Bruijn EA; Van Oosterom AT; Scalliet P
Anticancer Drugs; 1996 Jul; 7(5):586-90. PubMed ID: 8862727
[TBL] [Abstract][Full Text] [Related]
13. Determination of the new anticancer agent KW 2149, 7-N-[2-[2-(gamma-L-glutamylamino)ethyl)dithio)ethyl]mitomycin C, an analogue of mitomycin C.
Pattyn G; van Oosterom AT; de Bruijn EA; Tjaden UR
J Chromatogr; 1991 Mar; 564(1):352-4. PubMed ID: 1860933
[TBL] [Abstract][Full Text] [Related]
14. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X
Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Speers AG; Lwaleed BA; Featherstone JM; Cooper AJ
J Urol; 2007 Nov; 178(5):2171-5. PubMed ID: 17870115
[TBL] [Abstract][Full Text] [Related]
16. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum.
Masters JR; Know RJ; Hartley JA; Kelland LR; Hendriks HR; Connors T
Biochem Pharmacol; 1997 Feb; 53(3):279-85. PubMed ID: 9065731
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors.
Gontero P; Sargent JM; Hopster DJ; Lewandowic GM; Taylor CG; Elgie AW; Williamson CJ; Sriprasad SI; Muir GH
Anticancer Res; 2002; 22(6C):4073-80. PubMed ID: 12553035
[TBL] [Abstract][Full Text] [Related]
18. Severely contracted bladder following intravesical mitomycin C therapy.
Wajsman Z; McGill W; Englander L; Huben RP; Pontes JE
J Urol; 1983 Aug; 130(2):340-1. PubMed ID: 6410085
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies on the action of 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C and of mitomycin C on cultured HL-60 cells and isolated phage and plasmid DNA.
Ishioka C; Kanamaru R; Konishi Y; Ishikawa A; Shibata H; Wakui A
Cancer Chemother Pharmacol; 1990; 26(2):117-21. PubMed ID: 2112051
[TBL] [Abstract][Full Text] [Related]
20. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer.
Seraphim LA; Perrapato SD; Slocum HK; Rustum YM; Huben RP
J Urol; 1991 Mar; 145(3):613-7. PubMed ID: 1900087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
